Discovery of novel biomarkers in oral submucous fibrosis by microarray analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 9, 2008, Pages 2249-2259

  Li, Ning ^a   Jian, Xinchun ^a   Hu, Yanjia ^a   Xu, Chunjiao ^a   Yao, Zhigang ^a   Zhong, Xiaohuan ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Central South University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARTILAGE OLIGOMERIC MATRIX PROTEIN; CXCL9 CHEMOKINE; CYTOCHROME P450 3A5; CYTOKERATIN 19; LORICRIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; BETEL NUT; CHEEK MUCOSA; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENETICS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MOUTH DISEASE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; UPREGULATION; VALIDATION PROCESS;

ADOLESCENT; ADULT; ARECA; BLOTTING, WESTERN; CHI-SQUARE DISTRIBUTION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROARRAY ANALYSIS; ORAL SUBMUCOUS FIBROSIS; PRECANCEROUS CONDITIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 53349143385     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2908     Document Type: Article

References (50)

1. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC. Betel quid chewing, cigarette smoking, and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 1995;24:450-3.
2. Pindborg JJ, Sirsat SM. Oral submucous fibrosis. Oral Surg Oral Med Oral Pathol 1966;22:764-79.
3. Pindorg JJ. Oral submucous fibrosis: a review. Ann Acad Med Singapore 1989;18:603-7.
4. Reichart PA, Philipsen HP. Betel and Miang. Vanishing Thai habits. 2nd ed. Bangkok: White Lotus Ltd. Co; 2005.
5. Jian XC, Shen ZH, Liu SF. Oral submucous fibrosis - case reports. J Clin Stomatol 1985;1:12-3.
6. Jian XC, Liu SF, Shen ZH, et al. A clinical study of oral submucous fibrosis. Chin J Stomatol 1989;24:299-02.
7. Murti PR, Bhonsie RB, Pindborg JJ, Daftary DK, Gupta PC, Mehta FS. Malignant transformation rate in oral submucous fibrosis over a 17-year period. Community Dent Oral Epidemiol 1985;13:340-1.
8. Jin YT, Tsai ST, Wong TY, Chen FF, Chen RMY. Studies on promoting activity of Taiwan betel quid ingredients in hamster buccal pouch carcinogenesis. Eur J Cancer B Oral Oncol 1996;32B:343-6.
9. Jian XC, Peng JY, Tang ZG. Three cases of oral cancer associated with oral submucous fibrosis. West China J Stomatol 2000;18:130-1.
10. Katou F, Shirai N, Kamakura S, Tagami H, Nagura H, Motegi K. Differential expression of cornified cell envelope precursors in normal skin, intraorally transplanted skin and normal oral mucosa. Br J Dermatol 2003;148:898-905.
11. Hohl D, Lichti U, Breitkreutz D, Steinert PM, Roop DR. Transcription of the human loricrin gene in vitro is induced by calcium and cell density and suppressed by retinoic acid. J Invest Dermatol 1991;96:414-8.
12. Kao WB, Shieh YD, Hsia YJ, Shieh TY. The micro-array analysis of genetic change and proteins identification of oral submucous fibrosis. Int J Oral Maxillofac Surg 2005;34:139.
13. Tsai CH, Yang SF, Chen YJ, Chou MY, Chang YC. The upregulation of insulin-like growth factor-1 in oral submucous fibrosis. Oral Oncol 2005;41:940-6.
14. Yang SF, Hsieh YS, Tsai CH, Chou MY, Chang YC. The upregulation of type I plasminogen activator inhibitor in oral submucous fibrosis. Oral Oncol 2003;39:367-72.
15. Utsunomiya H, Tilakaratne WM, Oshiro K, et al. Extracellular matrix remodeling in oral submucous fibrosis: its stage-specific modes revealed by immunohistochemistry and in situ hybridization. J Oral Pathol Med 2005;34:498-07.
16. Liu SY, Lin MH, Yang SC, et al. Areca quid chewing enhances the expression of salivary matrix metalloproteinase-9. J Formos Med Assoc 2005;104:113-9.
17. Liu CJ, Lui MT, Chen HL, Lin SC, Chang KW. MICA and MICB overexpression in oral squamous cell carcinoma. J Oral Pathol Med 2007;36:43-7.
18. Tsai WC, Tsai ST, Ko JY, et al. The mRNA profile of genes in betel quid chewing oral cancer patients. Oral Oncol 2004;40:418-26.
19. Kozo Y, Daniel H, Wesley M, et al. The human loricrin gene. J Biol Chem 1992;267:18060-6.
20. Candi E, Melino G, Mei G, et al. Biochemical, structural, and transglutaminase substrate properties of human loricrin, the major epidermal cornified cell envelope protein. J Biol Chem 1995;270:26382-90.
21. Steinert PM, Marekov LN. The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide cross-linked components of the human epidermal cornified cell envelope. J Biol Chem 1995;270:17702-11.
22. Ishida YA, Takahashi H, Iizuka H. Loricrin and human skin diseases: molecular basis of loricrin keratodermas. Histol Histopathol 1998;13:819-26.
23. Oldberg A, Antonsson P, Lindblom K, Heinegård D. COMP (cartilage oligomeric matrix protein) is structurally related to the thrombospondins. J Biol Chem 1992;267:22346-50.
24. Di Cesare PE, Chen FS, Moergelin M, et al. Matrix-matrix interaction of cartilage oligomeric matrix protein and fibronectin. Matrix Biol 2002;21:461-70.
25. Holden P, Meadows RS, Chapman KL, Grant ME, Kadler KE, Briggs MD. Cartilage oligomeric matrix protein interacts with type IX collagen, and disruptions to these interactions identify a pathogenetic mechanism in a bone dysplasia family. J Biol Chem 2001;276:6046-55.
26. Hedbom E, Antonsson P, Hjerpe A, et al. Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 1992;267:6132-6.
27. Hummel KM, Neidhart M, Vilim V, et al. Analysis of cartilage oligomeric matrix protein (COMP) in synovial fibroblasts and synovial fluids. Br J Rheumatol 1998;37:721-8.
28. Smith RK, Zunino L, Webbon PM, Heinegård D. The distribution of cartilage oligomeric matrix protein (COMP) in tendon and its variation with tendon site, age and load. Matrix Biol 1997;16:255-71.
29. Farina G, Lemaire R, Korn JH, Widom RL. Cartilage oligomeric matrix protein is overexpressed by scleroderma dermal fibroblasts. Matrix Biol 2006;25:213-22.
30. Haque MF, Harris M, Meghji S, Barrett AW. Immunolocalization of cytokines and growth factors in oral submucous fibrosis. Cytokine 1998;10:713-9.
31. Chiang CP, Hsieh RP, Chen T H, et al. High incidence of autoantibodies in Taiwanese patients with oral submucous fibrosis. J Oral Pathol Med 2002;31:402-9.
32. Krenn V, Souto-Carneiro MM, Kim HJ, et al. Histopathology and molecular pathology of synovial B-lymphocytes in rheumatoid arthritis. Histol Histopathol 2000;15:791-8.
33. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002;2:106-15.
34. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000;18:593-20.
35. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM. Human Mig chemokine: biochemical and functional characterization. J Exp Med 1995;182:1301-4.
36. Rollins BJ. Chemokines. Blood 1997;90:909-28.
37. Gasperini S, Marchi M, Calzetti F, et al. Gene expression and production of the monokine induced by IFN-γ (MIG), IFN-inducible T cell α chemoattractant (I-TAC), and IFN-γ-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol 1999;162:4928-37.
38. Angiolillo AL, Sgadari C, Taub DD, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995;182:155-2.
39. Spandau U, Toksoy A, Goebeler M, Bröcker EB, Gillitzer R. MIG is a dominant lymphocyte-attractant chemokine in lichen planus lesions. J Invest Dermatol 1998;202:1003-9.
40. Goebeler M, Toksoy A, Spandau U, Engelhardt E, Bröcker EB, Gillitzer R. The CXC chemokine Mig is highly expressed in the papillae of psoriatic lesions. J Pathol 1998;183:89-95.
41. Haque MF, Meghji S, Khitab U, Harris M. Oral submucous fibrosis patients have altered levels of cytokine production. J Oral Pathol Med 2000;29:123-8.
42. Ohmori Y, Hamilton TA. A macrophage LPS-inducible early gene encodes the murine homologue of IP-10. Biochem Biophys Res Commun 1990;168:1261-7.
43. Mikihiroi, Yoshihiro O. Constitutive nuclear factor κB activity is required to elicit interferon-γ-induced expression of chemokine CXC ligand 9 (CXCL9) and CXCL10 in human tumour cell lines. J Biochem 2003;376:393-402.
44. Haque MF, Meghji S, Khitab U, Harris M. The human keratin genes and their differential expression. Curr Top Dev Biol 1987;22:5-34.
45. Lindberg K, Rheinwald JG. Suprabasal 40 kd keratin (K19) expression as an immunohistological marker of premalignancy in oral epithelium. Am J Pathol 1989;134:89-98.
46. Lindberg K, Rheinwald JG. Three distinct keratinocyte subtypes identified in human oral epithelium by their patterns of keratin expression in culture and in xenografts. Differentiation 1991;45:230-41.
47. Michel M, Török N, Godbout MJ, et al. Keratin 19 as a biochemical marker of skin stem cells in vivo and in vitro : keratin 19 expressing cells are differentially localized in function of anatomic sites, and their number varies with donor age and culture stage. J Cell Sci 1996;109:1017-28.
48. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360:1155-62.
49. Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002;3:561-97.
50. Parke DV. The cytochromes P450 and mechanisms of chemical carcinogenesis. Environ Health Perspect 1994;102:852-3.